<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13392">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02059707</url>
  </required_header>
  <id_info>
    <org_study_id>RS-003 V1.0_30Oct2012</org_study_id>
    <nct_id>NCT02059707</nct_id>
  </id_info>
  <brief_title>LARIAT RS: An Observational Study of the Performance and Safety of the LARIAT RS</brief_title>
  <official_title>LARIAT RS: An Observational Study of the Performance and Safety of the LARIAT RS Suture Delivery Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SentreHEART, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SentreHEART, Inc.</source>
  <oversight_info>
    <authority>Poland: Office of Registration of Medicinal Products, Medical Devices and Biocides</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to assess the effectiveness of permanent exclusion of the LAA with the
      LARIAT RS Suture Delivery Device and accessories in AF patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, observational, single-center, non-randomized study of a stand-alone procedure
      for the exclusion of the LAA with the LARIAT RS in patients with atrial fibrillation.
      Completed LAA exclusion will be assessed by TEE.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Percent of subjects with complete exclusion</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess the rate of complete exclusion of the LAA measured by color duplex TEE at 4 time points: Acute (i.e., immediately after LAA exclusion procedure), 1 day, 1 month, and 3 month.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Exploratory objectives of procedural success and device-related complication rates</measure>
    <time_frame>3 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The rate of procedural success
The rate of complications related to the use of the LARIAT RS and accessories</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atrial Appendage</condition>
  <arm_group>
    <arm_group_label>LAA exclusion procedure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LAA exclusion with the LARIAT RS Suture Delivery Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LARIAT RS Suture Delivery Device</intervention_name>
    <description>LARIAT RS Suture Delivery Device</description>
    <arm_group_label>LAA exclusion procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 21 years

          2. Diagnosed non-valvular atrial fibrillation

          3. Current CHADS2 score ≥ 2

          4. Poor candidate (e.g., contraindicated, labile INR, non-compliant, etc.) for
             anticoagulation (e.g., warfarin, dabigatran, apixaban, and rivaroxaban)

          5. Life expectancy of ≥ 1 year

          6. Willing and able to provide written informed consent

          7. Willing and able to come to and comply with scheduled follow-up visits

        Exclusion Criteria:

          1. Previous cardiac surgery involving opening of pericardium (e.g., CABG, heart
             transplantation, valve surgery)

          2. Prosthetic heart valve or ring in any position

          3. Current NYHA Class IV heart failure symptoms

          4. Current right heart failure

          5. Myocardial infarction or unstable angina within last 3 months

          6. Current cardiogenic shock or hemodynamic instability

          7. Current symptomatic carotid disease

          8. Need for an intra-aortic balloon pump or intravenous inotropes

          9. Embolic stroke or transient ischemic attack (TIA) within the last 30 days.

         10. Current diagnosis of active systemic infection

         11. Need for emergent cardiac surgery (e.g., cardiogenic shock)

         12. Current renal failure requiring dialysis

         13. Current clinical evidence of cirrhosis

         14. Any history of thoracic radiation

         15. Current use of long term treatment with steroids, not including intermittent use of
             inhaled steroids for respiratory diseases

         16. Diagnosed autoimmune disease known to be associated with pericarditis (i.e., specific
             connective tissue disorders)

         17. Any history of pericarditis

         18. Pectus excavatum  (clinically defined by treating physician)

         19. Severe scoliosis

         20. Pregnancy or desire to get pregnant within the next 12 months.

         21. LVEF &lt; 30%

         22. Current participation in a clinical investigation that involves an active treatment
             arm.

         23. Mental impairment or other conditions, which may not allow patient to understand the
             nature, significance and scope of the study

         24. Any other criteria, which would make the patient unsuitable to participate in this
             study as determined by clinical site Principal Investigator  (e.g., an uncontrolled
             drug and/or alcohol addiction)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jagiellonian University (John Paul II) Hospilal</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 7, 2014</lastchanged_date>
  <firstreceived_date>February 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
